Malta - English - Medicines Authority

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - albumin, human - solution for infusion - albumin, human 20 g/100ml - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - albumin, human - solution for infusion - albumin, human 20 g/100ml - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - factor viii, human - powder and solvent for solution for infusion - factor viii, human 1000 iu - antihemorrhagics

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

kedrion, italy - human plasma coagulation factor ix - powder and solvent for solution for infusion - 500 iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

kedrion, italy - albumin human - solution - 20 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

kedrion, italy - albumin human - solution - 20 %

Kenya - English - Pharmacy and Poisons Board

kedrion s.p.a loc. ai conti - castelvecchio pascoli , 55051 - human albumin bulk solution - solution for infusion - 200g/l ( 20%) solution for infusion - albumin

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

kedrion, italy - human plasma coagulation factor ix - powder and solvent for solution for infusion - 500 iu

United States - English - NLM (National Library of Medicine)

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 10 g in 50 ml - emergency treatment of hypovolemic shock albuked 20 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (albuked™ 5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual; i.e., about 2 g per kg body weight in the absence of active bleeding. although albuked 5 is to be preferred for the usual volume deficits, albuked 20 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic fluid from a

United States - English - NLM (National Library of Medicine)

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 2.5 g in 50 ml - emergency treatment of hypovolemic shock albuked 5 is iso-oncotic with normal plasma and on intravenous infusion will expand the circulating blood volume by an amount approximately equal to the volume infused. in conditions associated mainly with a volume deficit, albumin is best administered as a 5% solution (albuked 5); but where there is an oncotic deficit, albumin (human) 25%, usp (albuked™ 25) may be preferred. this is also an important consideration where the treatment of the shock state has been delayed. if albuked 25 is used, appropriate additional crystalloid should be administered.(1) crystalloid solutions in volumes several times greater than that of albuked 5 may be effective in treating shock in younger individuals who have no preexisting illness at the time of the incident. older patients, especially those with preexisting debilitating conditions, or those in whom the shock is caused by a medical disorder, or where the state of shock has existed for some time before active therapy could be insti